On 6th November last year IMU announced a complete response in...

On 6th November last year IMU announced a complete response in the MAST study. The bile tract cancer had been completely cleared for 350 days. This means that LC and management knew about this for about a year leading up to that announcement but couldn’t say anything. One wonders what information they are sitting on now that they are unable to reveal due to tight FDA regulations?

Since then they achieved FDA fast track and have been able to refine the study design and the first patient was dosed in early July in that expansion trial.

They’ve also stated on presentations that expansions into other indications are in the works. Bladder cancer has been specifically mentioned. Would they be expanding into other indications if Vaxinnia wasn’t working?

CF33 is second in the presentations because Azer Cell is the closest to market and commercialisation. Makes perfect sense. Hopefully generate revenue from a deal which can then fund the other platforms.

The SP is disappointing for sure but I believe we’ll have significant news in the next 4 months, starting with an update on the Azer Cell trail.

Warren Buffet famously said if the SP doesn’t match the fundamentals it’s an opportunity.